Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Innate Pharma currently manages 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. This portfolio is distributed across 3 distinct examiners and 3 distinct art units. HOLLAND, PAUL J is identified as the busiest examiner for this applicant, currently handling 1 pending office action.
The distribution of 3 pending office actions across 3 distinct examiners suggests that prosecution strategies are tailored to individual examiner preferences. With 1 pending action assigned to HOLLAND, PAUL J, the workload is spread across the distinct examiners involved.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HOLLAND, PAUL J | 1 | 57.5% | +64.6% |
| CHANDRA, GYAN | 1 | 71.3% | +27.5% |
| NATARAJAN, MEERA | 1 | 62.5% | +18.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18622013 | METHODS FOR PURIFYING HETEROMULTIMERIC ANTIBODIES | HOLLAND, PAUL J | — |
| 18164649 | NEUTRALIZATION OF INHIBITORY PATHWAYS IN LYMPHOCYTES | NATARAJAN, MEERA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18622013 | METHODS FOR PURIFYING HETEROMULTIMERIC ANTIBODIES | HOLLAND, PAUL J | — |
| 18285668 | IMMUNOHISTOCHEMISTRY METHODS AND KIR3DL2-SPECIFIC REAGENTS | CHANDRA, GYAN | — |
| 18164649 | NEUTRALIZATION OF INHIBITORY PATHWAYS IN LYMPHOCYTES | NATARAJAN, MEERA | — |
| Art Unit | Apps |
|---|---|
| 1656 | 1 |
| 1674 | 1 |
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18622013 | METHODS FOR PURIFYING HETEROMULTIMERIC ANTIBODIES | HOLLAND, PAUL J | 1656 | §102§103§112 | Non-Final OA | — | Pending | Mar 29, 2024 |
| 18285668 | IMMUNOHISTOCHEMISTRY METHODS AND KIR3DL2-SPECIFIC REAGENTS | CHANDRA, GYAN | 1674 | §112 | Final Rejection | — | Pending | Oct 05, 2023 |
| 18164649 | NEUTRALIZATION OF INHIBITORY PATHWAYS IN LYMPHOCYTES | NATARAJAN, MEERA | 1643 | §102§103§112 | Non-Final OA | — | Pending | Feb 06, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial